

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 August 2021 (26.08.2021)



(10) International Publication Number
WO 2021/168128 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 35/28 (2015.01)
C07K 14/705 (2006.01) A61P 37/06 (2006.01)
C12N 5/0775 (2010.01)

(21) International Application Number:

PCT/US2021/018599

(22) International Filing Date:

18 February 2021 (18.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/978,141 18 February 2020 (18.02.2020) US
63/062,845 07 August 2020 (07.08.2020) US

(71) Applicant: MAGENTA THERAPEUTICS, INC.

[US/US]; 100 Technology Square, 5th Floor, Cambridge,
Massachusetts 02139 (US).

(72) Inventors: GILLARD, Geoffrey O.; 345 Ayer Road, (P.O.

Box 836), Harvard, Massachusetts 01451 (US). PROC-
TOR, Jennifer Lynn; 36 Saint Francis Street, Medford,
Massachusetts 02155 (US). HYZY, Sharon; 15 Quarry
Lane, Apt. 6118, Malden, Massachusetts 02148 (US). BOI-
TANO, Anthony; 27 Evelyn Road, Newton, Massachusetts
02468 (US). COOKE, Michael; 1387 Washington St., Unit
202, Boston, Massachusetts 02118 (US).

(74) Agent: ERICKSON, Briana M. et al.; Womble Bond

Dickinson (US) LLP, Independence Wharf, 470 Atlantic
Avenue, Suite 600, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2021/168128 A1

(54) Title: COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATION

(57) Abstract: Described herein are compositions and methods useful for the depletion of CD45+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. The compositions and methods described herein can be used to treat a disorder, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for allogeneic hematopoietic stem cell transplant therapy and to improve the engraftment of allogeneic hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.